Reasons for Discontinuation of dupilumab in Adult Atopic Dermatitis in Clinical Practice.
Fiche publication
Date publication
novembre 2021
Journal
The British journal of dermatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François
Tous les auteurs :
Marniquet ME, Seneschal J, Darrigade AS, Staumont-Sallé D, Jachiet M, Nosbaum A, Tauber M, Abasq C, Ferrier Le Bouedec MC, Droitcourt C, Aubert H, Bernier C, Soria A, Raison-Peyron N, Tétart F, Aubin F, Viguier M, Valois A, Kupfer-Bessaguet I, Goronflot T, Barbarot S,
Lien Pubmed
Résumé
Dupilumab, an anti-IL-4ɑ monoclonal antibody, has shown a positive benefit-risk ratio when treating moderate to severe atopic dermatitis (AD) in clinical studies (1). High persistence on dupilumab has recently been reported in clinical-practice setting with 77% of patients remaining in treatment for 12 months in a retrospective study including 1,963 patients with AD but reasons for discontinuation were not investigated (2).
Référence
Br J Dermatol. 2021 Nov 8;: